Etiology and familial inheritance of pleomorphic adenomas

Authors

  • Krysten Clark University of Pittsburgh, School of Dental Medicine

DOI:

https://doi.org/10.5195/d3000.2017.70

Keywords:

Pleomorphic Adenoma, Carcinoma ex Pleomorphic Adenoma, PLAG1

Abstract

Background: A pleomorphic adenoma is the most common salivary gland neoplasm in both children and adults. Pleomorphic adenomas are derived from ductal and myoepithelial cells and are most commonly found in the superficial lobe of the parotid gland. The purpose of this article is to discuss the genes involved in pleomorphic adenomas and the possible autosomal dominant mode of inheritance. Case Description: The first patient was a white male who was diagnosed with carcinoma ex pleomorphic adenoma, a highly aggressive tumor, at the age of 57. He had an undiagnosed pleomorphic adenoma for approximately 15 years prior. The tumor was excised and the patient underwent radiation in the location of his parotid gland for 4 years until he deceased. The second patient is a white female, his daughter, who was diagnosed with a benign pleomorphic adenoma at the age of 46. Her salivary gland tumor was excised and normal follow up appointments occurred. Practical Implications: Pleomorphic adenomas most commonly affect the parotid gland, the largest of the three major salivary gland tumors. Occurrence and excision of this salivary gland tumor will cause a decrease in the secretion of saliva, leading to a dry mouth and an increased risk of caries.

Author Biography

Krysten Clark, University of Pittsburgh, School of Dental Medicine

University of Pittsburgh School of Dental Medicine

References

PLAG1 gene alterations in salivary gland pleomorphic adenoma and carcinoma ex-pleomorphic adenoma: a combined study using chromosome banding, in situhybridization and immunocytochemistry. Martins C, Fonseca I, Roque L, Pereira T, Ribeira C, Bullerdiek J, Soares J. Modern Pathology. 2005; 18:1048–1055. 6 May 2006. PMID: 15920557.

Salivary gland tumors in survivors of childhood cancer. Whatley WS, Thompson JW, Rao B. 2006 March; 124 (3):385-388. PMID: 16500432

Smoking and risk of parotid gland tumors: a nationwide case-control study. Sadetzki S, Oberman B, Mandelzweig L, Chetrit A, Ben-Tal T, Jarus-Hakak A, Duvdevani S, Cardis E, Wolf M. 2008 May 1; 112(9): 1974-82. PMID: 18361448

Simian Virus 40 Sequences and Expression of the Viral Large T Antigen Oncoprotein in Human Pleomorphic Adenomas of Parotid Glands. Martinelli, M, Martini, F, Rinaldi, E, Caramanico, L, Magri, E, Grandi, E, Carinci F, Pastore A, Tognon, M. 2002 Oct; 161(4): 1127–1133. PMID: PMC1867276

Conserved mechanism of PLAG1 activation in salivary gland tumors with and without chromosome 8q12 abnormalities: identification of SII as a new fusion partner gene. Astrom AK, Voz ML, Kas K, Roijer E, Wedell B, Mandahl N, Van de Ven W, Mark J, Stenman G. 1999 Feb 15; 59(4): 918-923. PMID 10029085

Lodish H, Berk A, Zipursky SL, Matsudaira P, Baltimore D, Darnell J (2000) Molecular Cell Biology. New York: W. H. Freeman.

PLAG1 gene alterations in salivary gland pleomorphic adenoma and carcinoma ex-pleomorphicadenoma: a combined study using chromosome banding, in situ hybridization and immunocytochemistry. Martins C, Fonseca I, Roque L, Pereira T, Ribeiro C, Bullerdiek J, Soares J. 2005 Aug; 18(8): 1048-1055. PMID: 15920557

Aberrant PLAG1 expression in pleomorphic adenomas of the salivary gland: a molecular genetic and immunohistochemical study. Matsuyama A, Hisaoka M, Nagao Y, Hashimoto H. 2011 May; 458(5): 583-92. PMID 21394649

Mucin expression in pleomorphic adenoma of salivary gland: a potential role for MUC1 as a marker to predict recurrence. Hamada T, Matsukita S, Goto M, Kitajima S, Batra S K, Irimura T, Sueyoshi K, Sugihara K, Yonezawa S. 2004; 57(8), 813–821. PMID PMC1770389

Downloads

Published

2017-06-14

Issue

Vol 5, No 1 (2017)

Section

Mechanisms of Oral Disease

License

Authors who publish with this journal agree to the following terms:

  1. The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
  2. Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
  3. The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
    1. Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site;
    with the understanding that the above condition can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
  4. The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgement of its initial publication in this journal.
  5. Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
  6. Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
  7. The Author represents and warrants that:
    1. the Work is the Author’s original work;
    2. the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
    3. the Work is not pending review or under consideration by another publisher;
    4. the Work has not previously been published;
    5. the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
    6. the Work contains no libel, invasion of privacy, or other unlawful matter.
  8. The Author agrees to indemnify and hold Publisher harmless from Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.

Revised 7/16/2018. Revision Description: Removed outdated link.